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Abstract
Purpose Cystic Fibrosis (CF) is a multisystem disease associated with symptoms such as dyspnoea, tachycardia and tachyp-
nea that may be related to changes in autonomic function and sensitive to improvement following inspiratory muscle training 
(IMT). The aim of the present study was to investigate the effect of IMT on heart rate variability (HRV) and respiratory 
function in children.
Methods Five CF and five matched controls (40% boys) performed a 4-weeks IMT programme, involving 30 breaths, twice 
a day. Weeks 1–2 of training were set at 40% of a participant’s maximal strength index (S.Index), with week’s 3–4 set at 
50%. Participants wore an ActiHeart for three consecutive days at baseline and post-intervention and indices of HRV were 
derived. Standard measures of lung function were obtained along with health-related quality of life (HRQoL) using the 
CF-specific questionnaire (CFQ-R).
Results IMT elicited clinically meaningful increases in respiratory muscle strength and respiratory symptom domain scores, 
but no improvements in respiratory volume, irrespective of group. Similarly, no significant improvements were found in 
HRQoL despite 62.5% of the population increased their HRQoL score. Post-intervention, CF participants showed a clinically 
meaningful decrease in the very low frequency (VLF) domain.
Conclusion These results may indicate clinically meaningful changes in HRV and inspiratory muscle strength following a 
4-week IMT intervention, although a more powerful study is required to draw further conclusions. Indeed, the trends for 
improved HRQoL support the need for such studies to ascertain the potential therapeutic role of IMT in those with CF.
Keywords Cardiac function · Paediatrics · Chronic disease · Quality of life · Respiratory muscle training
Introduction
Cystic Fibrosis (CF) is the most common, inherited, life-
shortening condition among Caucasians, with an estimated 
population of 10,469 in the UK alone [9]. It is a multisystem 
disease affecting the respiratory, gastrointestinal, reproduc-
tive tract and sweat glands [22]. In addition to respiratory 
dysfunction, cardiac damage may also be present in those 
with CF, with primary symptoms including dyspnoea, 
tachycardia and tachypnoea [20]. Such symptoms may be 
attributed to β-2 agonist use, with hypoxemia potentially 
exacerbating cardiac autonomic dysfunction [20].
In those with CF, the autonomic nervous system may be 
influenced by the interaction between cardiac and pulmo-
nary dysfunction [20]. Heart rate variability (HRV) provides 
an insight to the autonomic nervous system and can pro-
vide an early indication of damage to the cardiac system 
[58] and increased risk of cardiac mortality [57]. However, 
whether CF is associated with derangements in autonomic 
nervous system function is equivocal, with some reporting 
similar sympathovagal function during a six-minute walk 
test (6MWT) [20], whilst others found higher sympathetic 
[46] and/or lower parasympathetic tone in children with CF 
at rest and during recovery [20]. In adults with CF, further 
derangements in autonomic functions have yet to be dem-
onstrated in children with CF, which may reflect age-related 
modulations and/or the progression of the disease itself [33]. 
Alternatively, or additionally, the apparent age-related dif-
ferences may reflect differences in fitness [26] or the impact 
of medication [50]. Irrespective of the mechanisms for these 
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differences, it is suggested that deleterious adaptations in 
HRV are associated with an increased risk of cardiovascular 
complications [39]. Therefore, improving HRV in those with 
CF is paramount to their physiological and psychological 
health.
Inspiratory muscle training (IMT), a breathing exercise 
that aims to strengthen the respiratory muscles by using a 
restricted airflow breathing technique to increase the load 
placed upon the intercostal muscles and diaphragm, has 
been shown to stimulate a hypertrophic response [18]. In 
adults with hypertension and diabetes, IMT has been shown 
to significantly enhance cardiac autonomic modulation in 
comparison to unloaded IMT [19, 30]. Furthermore, a res-
piratory muscle feedback and breathing retraining program 
in adults with CF elicited significant improvements in forced 
expiratory volume in 1 s  (FEV1) and mean expiratory flow 
during forced vital capacity (FVC) compared to an age and 
severity matched control group [16]. In children with CF, 
IMT increases inspiratory muscle strength (IMS) [51, 52], 
vital capacity, total lung capacity and exercise tolerance 
[52], as well as respiratory muscle endurance [5]. In healthy 
individuals and those with heart failure, improvements in 
respiratory muscle function following a 12-weeks IMT are 
associated with an enhanced metaboreflex activation thresh-
old, resulting in decreased cardiac sympathetic output at rest 
[14, 25, 61]. However, whether similar beneficial adapta-
tions to automatic nervous system (ANS) control following 
IMT are observed in those with CF remains to be elucidated.
In addition to potential physiological adaptations, IMT 
has also been suggested to elicit positive benefits on quality 
of life (QoL) [15], anxiety and depression in CF adults [17]. 
Little data is available in children with CF, but a weak cor-
relation between HRV and QoL has been observed in healthy 
children and adolescents, with suggestions that a stronger 
correlation would be evident in chronically ill children [54]. 
Interventions that simultaneously promote improvements in 
lung function and QoL are highly desirable, especially for 
those with CF who already face a substantial, time consum-
ing, treatment schedule.
Therefore, the aim of this study was to ascertain the 
effects of IMT on cardiac autonomic control (HRV), lung 
function and QoL in children with CF compared to their 
healthy counterparts.
Materials and Methods
Five CF and five matched control participants aged 
10.4 ± 1.2 years (40% boys) were recruited from a CF unit 
in South Wales, from a local school and through University 
staff emails, respectively. Participants were recruited on the 
basis of meeting the following criteria: (1) documented clini-
cal features of CF as well as an abnormal sweat test (sweat 
sodium and chloride 60 mmol/L); (2) absence of any addi-
tional known illness/or disease in CF patients or absence 
of any known illness or disease in healthy controls; and (3) 
voluntary participation and consent to comply with the study 
protocol. Ethical approval was obtained from the Bromley 
National Health Service Research Ethics Committee (REC 
reference: 13/LO/1907) and written informed assent and 
consent were obtained from participants and their parents/
guardian, respectively. Participants were required to attend 
two testing visits in total (baseline and post-intervention), 
which both took place within a week before the first or after 
the last IMT session.
Participants were supplied with their own personal POW-
ERbreathe Plus device (POWERbreathe Plus LR Level 1, 
Gaiam Ltd. E & OE, UK) and undertook a familiarisation 
session to ensure that they were comfortable with the train-
ing and device. Participants were encouraged to practice 
breathing technique and ask any questions until they were 
comfortable with the regime, which involved 30 breaths 
twice a day, for 28 consecutive days. The device resistance 
was determined by the participants baseline strength index 
(S.Index). Specifically, the first two weeks of the training 
programme were performed at 40% of participant’s pre-IMT 
maximal S.Index, with the remaining two weeks at 50%.
Anthropometrics
Anthropometrical characteristics were measured according 
to standard procedures pre- and post-intervention. Specifi-
cally, body mass was measured to the nearest 0.01 kg (Seca 
899 flat scale, Seca, UK), stature and sitting stature were 
measured to the nearest 0.01 m (Seca portable stadiometer, 
Seca, UK). Waist and hip circumference were measured to 
the nearest 0.01 m using a non-elastic anthropometric tape 
(Seca Ltd, Birmingham, UK) at the narrowest point between 
the bottom of the ribs and the iliac crest and around the wid-
est point of the buttocks [59]. Maturity offset was calculated 
using the equations developed by Moore et al. [37] (Table 1).
Heart Rate Variability
Participants were required to wear an ActiHeart (Actiheart4, 
Camntech Ltd, Cambridge, UK) recording at 126 Hz for 
three consecutive days. The ActiHeart, which has high intra-
and inter-instrument reliability and demonstrates good valid-
ity [6], comprises of two standard ECG electrodes adhered 
at V1 or V2 positions and approximately 10 cm away on the 
left side at V4 or V5. This specific placement ensures a bet-
ter signal to noise ratio, free from movement artefacts and 
with higher ECG amplitudes [6]. At least two complete 24-h 
RR recordings were used to obtain HRV parameters which 
were subsequently averaged. The analogue signal from the 
ActiHeart was band-pass filtered (10–35 Hz) and processed 
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by a real time QRS-detection algorithm. The RR data also 
underwent visual examination in order to verify the accu-
racy of the data prior to subsequent analysis. When the RR 
interval(s) was anomalous, the RR data points were removed 
from the data set. Indices of HRV were derived from the fre-
quency domain [very low frequency (VLF, 0.017–0.04 Hz), 
low frequency (LF, 0.04–0.15 Hz), high frequency (HF, 
0.15–0.4 Hz) power, LF:HF ratio] according to the guide-
lines of the Task Force [57] and presented as relative val-
ues. Prior to the frequency domain analysis procedures RR 
interval data were re-sampled using a sampling frequency of 
2 Hz and then linearly de-trended and windowed in consecu-
tive one-minute segments; the power spectral density of each 
segment was then calculated using the Welch periodogram 
method, using short-term Fourier transformation and a 50% 
overlap between adjacent segments.
Inspiratory Function Measurements
Inspiratory muscle function and capacity were measured 
using the POWERbreathe K5 (HaB International Ltd, UK). 
The K5 was programmed with the participant’s age, stature, 
mass and sex, and, following a familiarisation session, three 
maximal inspiratory efforts were performed. Inspiratory vol-
ume (L), flow rate (L/s) and S.Index  (cmH2O) were recorded 
and the average calculated across all three tests (Table 1).
Cystic Fibrosis Questionnaire—Revised (CFQ‑R)
All participants completed the age-appropriate version of the 
CFQ-R [35, 41], a disease-specific patient reported outcome 
designed to measure the physical, social and emotional impact 
of CF on a four point Likert, true–false or frequency scale. The 
CFQ-R child version consists of 35 items grouped into the 
following categories: (i) physical symptoms (6); (ii) emotional 
functioning (8); (iii) social functioning (7); (iv) body image 
(3); (v) eating disturbance (3); (vi) treatment burden (3); (vii) 
respiratory (4); and (viii) digestive symptoms (1). Those par-
ticipants aged 6–11 years undertook an interviewer-adminis-
tered version of the CFQ-R, whilst 12-year olds completed 
the self-report version. Control participants were excluded 
from treatment specific questions and their overall score was 
made relative to account for the reduced number of questions 
completed. Moreover, parent/guardians completed a 44-item 
CFQ-R questionnaire based on their perceptions of their 
child’s QoL. Raw scores from the CFQ-R Child and Parent/
guardian questionnaires were standardised to a 0–100 scale, 
with a higher score indicative of a higher HRQoL. For the 
respiratory symptom domain, the minimal clinically important 
difference (MCID) was defined as a change of 4.0 points [42].
Data Analysis
Between group characteristics and anthropometrics were 
compared at baseline using an independent t-test. A repeated 
measures ANOVA was used to analyze lung function and 
HRV in response to the IMT intervention and their interac-
tion with disease status. The MCIDS were calculated using 
distribution-based methods. Specifically, changes in HRV and 
lung function from baseline to follow-up were calculated as 
0.5 multiplied by SD of baseline. Scores are shown as the 
proportion of individuals whose scores exhibited a clinically 
meaningful increase or decrease, in lung function or HRV 
of ≥ 0.05 SD. Effect size was calculated using the mean change 
in scores divided by the SD of baseline scores [11]. For inter-
preting effect sizes, Cohen (1988) has proposed the following 
benchmarks: 0.2 (small), 0.50 (moderate) and 0.80 (large). 
A moderate effect size is considered a clinically important 
effect [23]. Pearson’s correlation coefficients were used to 
assess the relationship between CFQ-R domains, HRV and 
lung function, with Cronbach’s Alpha used to measure internal 
consistency within the questionnaires [12]. Internal consist-
ency was good for CF children (α = 0.83–0.98), CF parents 
(α = 0.92–0.95), control children (α = 0.72–0.79) and adequate 
for control parents (α = 0.55–0.59). For the CFQ-R, change 
scores were compared to established MCID scores in the pae-
diatric CF population [36, 42]. All data was analysed using a 
statistical software package (IBM SPSS, Version 25.0) and is 
presented as Mean ± SD. Statistical significance was accepted 
as P < 0.05.
Results
Lung Function
There was no significant difference in lung function 
between those with and without CF at baseline. IMT 
Table 1  Participant characteristics of those with Cystic Fibrosis (CF) 
and their healthy peers (Mean ± SD)
BMI body mass index, CF cystic fibrosis, W:H waist-hip ratio, 
S.Index strength index
Total CF Healthy controls
Age (years) 10.4 ± 1.2 10.8 ± 1.2 10.0 ± 1.1
Mass (kg) 40.3 ± 7.3 43.9 ± 3.6 36.7 ± 8.2
Stature (m) 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1
BMI (kg/m) 18.3 ± 2.1 19.6 ± 1.4 16.9 ± 1.8
Maturity offset (years) − 1.9 ± 1.1 − 1.9 ± 0.9 − 1.9 ± 1.3
W:H (cm/cm) 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.2
S.Index  (cmH2O) 51.7 ± 12.4 57.9 ± 1.1 46.8 ± 15.0
Flow rate (L/s) 2.9 ± 0.8 3.4 ± 0.1 2.5 ± 0.9
Volume (L) 1.1 ± 0.6 1.4 ± 0.7 0.9 ± 0.4
 Journal of Science in Sport and Exercise
1 3
elicited increases in lung function, irrespective of group. 
Specifically, in those with CF, S.Index and flow rate signif-
icantly increased by 18.3% and 18.1%, respectively, whilst 
in the healthy children, S.Index and flow increased by 31% 
and 57%, respectively (Table 2). In contrast, there was not 
a significant intervention effect on volume in either group. 
All CF participants exhibited a large clinically meaning-
ful increase in S.Index (d = 8.0) and flow rate (d = 9.9), 
but only 25% showed a clinically meaningful increase 
in volume which was associated with a small effect size 
(d = 0.3). When the absolute magnitude of change was 
considered, the healthy children demonstrated greater 
increases in flow rate (1.0 ± 0.9 vs. 0.6 ± 0.3 L/s; P < 0.05) 
and S.Index (14.8 ±11.3 vs. 10.5 ± 5.6  cmH2O; P < 0.05) 
than those with CF.
Heart Rate Variability
At baseline, frequency domain measures were not signifi-
cantly different between those with CF and their healthy 
peers. A repeated measures ANOVA with a Green-
house–Geisser correction determined that frequency domain 
indices did not differ significantly between time-points. Spe-
cifically, while IMT in those with CF was associated with an 
increase in VLF (1.7%), HF (1.8%) and LF:HF (0.2), and a 
reduction in LF (− 1.6%)  post-intervention, these were not 
statistically significant. However, changes in VLF exhibited 
a moderate clinically meaningful decrease (d = 0.6), while 
other HRV parameters exhibited small to trivial clinical 
effect in CF (Table 3). In contrast, in the healthy group, 
reductions in VLF (− 2.7%) and LF:HF (− 0.29) and an 
Table 2  Lung function variables pre- and post- the inspiratory muscle training intervention in children with Cystic Fibrosis (CF) and healthy 
controls (Mean ± SD)
S.Index strength index. *P < 0.05.
Lung function 
indices
Baseline Post Mean change % of participants with clinically 
significant increase (≥ 0.05)
% of participants with clinically 
significant decrease (≤ 0.05)
Effect size
Cystic fibrosis
S.Index (cmH2O) 57.9 ± 1.3 68.4 ± 5.4* 10.5 ± 5.6 100% 0% 8.0
Flow rate (L/s) 3.4 ± 0.1 4.0 ± 0.3* 0.6 ± 0.3 100% 0% 9.9
Volume (L) 1.4 ± 0.8 1.6 ± 0.6 0.2 ± 0.4 25% 0% 0.3
Control
S.Index (cmH2O) 47.8 ± 19.1 62.6 ± 7.9* 14.8 ± 11.3 60% 25% 0.9
Flow rate (L/s) 2.5 ± 1.1 3.5 ± 0.4 1.0 ± 0.9 60% 0% 1.0
Volume (L) 0.9 ± 0.5 1.0 ± 0.3 0.2 ± 0.4 40% 20% 0.4
Table 3  Relative frequency domain indices of HRV pre- and post- the inspiratory muscle training intervention in children with Cystic Fibrosis 
(CF) and healthy controls (Mean ± SD)
VLF very low frequency, LF low frequency, HF high frequency, LF:HF low to high frequency ratio
HRV indices Baseline Post Mean change % of participants with clinically 
significant increase (≥ 0.05)
% of participants with clinically 
significant decrease (≤ 0.05)
Effect size
Cystic fibrosis
VLF (%) 20.2 ± 0.8 21.9 ± 5.9 1.7 ± 1.5 25% 75% 0.6
LF (%) 59.7 ± 3.4 58.1 ± 3.3 − 1.6 ± 9.5 25% 50% − 0.002
HF (%) 20.2 ± 5.1 22.0 ± 4.0 1.8 ± 3.9 25% 25% 0.04
LF:HF (%/%) 3.2 ± 0.8 3.4 ± 0.6 − 0.2 ± 10.1 25% 50% − 0.2
Control
VLF (%) 18.6 ± 3.0 15.9 ± 1.5 − 0.3 ± 0.3 25% 50% − 0.8
LF (%) 59.6 ± 4.8 60.3 ± 1.8 − 2.8 ± 4.0 0% 25% − 0.3
HF (%) 21.7 ± 2.6 23.8 ± 2.5 0.7 ± 3.8 75% 25% 1.0
LF:HF (%/%) 2.9 ± 0.5 2.6 ± 0.3 2.1 ± 1.1 0% 50% − 0.5
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increase in LF (0.7%) and HF (2.1%) were observed post-
IMT but were not statistically significant.
CFQ‑R
There was no significant difference in HRQoL over time, 
irrespective of disease status. However, 62.5% of the popu-
lation increased their HRQoL post-intervention. At base-
line, the CFQ-R respiratory domain demonstrated a weak 
negative correlation with S.Index (r = − 0.29) and flow rate 
(r = − 0.23) and a weak positive correlation with volume 
(r = 0.24). After the intervention, the respiratory domain 
of the CFQ-R showed a strong negative correlation with 
S.Index (r = − 0.85; P = 0.008) and flow rate (r = − 0.84; 
P = 0.009). The respiratory symptom domain change score 
indicated that CF participants perceived clinically meaning-
ful improvements.
Similar to their children, parent/guardian’s perceptions 
of their child’s HRQoL did not differ between time-points. 
The CF group showed no significant difference in per-
ceived HRQoL between child and parents at baseline (child 
88.9% ± 7.5%; parent 90.9% ± 7.7%) or post-intervention 
(child 89.3% ± 8.8%; parent 90.7% ± 8.4%).
Discussion
The main finding of this pilot study was that IMT elicited 
clinically meaningful improvements in S.Index and flow 
rate, indicative of improvements in IMS, irrespective of 
health status. Whilst the mechanistic basis of these changes 
in lung function remains to be elucidated, there were some 
indications of changes in parasympathetic modulation, 
although these were not significant and a clinically mean-
ingful decrease in sympathetic modulation. In line with the 
changes in lung function, IMT elicited a perceived improve-
ment in the respiratory symptom domain in CF participants. 
Overall, the current study provides preliminary indications 
that the benefits of IMT should be considered to extend to 
cardiovascular, as well as respiratory, function, and high-
lights that further work is warranted to ascertain the poten-
tial therapeutic benefits of IMT for children with CF.
The significant improvements in S.Index following the 
4-weeks IMT intervention are congruent with previous 
research in adults [1, 15, 17, 52] and children with CF [1]. 
Indeed, Asher et al. [1] found significant improvements 
in IMS and endurance following a 4-weeks training pro-
gramme of 15 min twice per day, in children and adults 
with CF. However, in contrast to the present study, Asher 
et al. [1] used a substantially higher training intensity of 
80% maximal inspiratory pressure (MIP). Similarly, Sawyer 
and Clanton [52] reported improvements in IMS following 
a protocol involving 60% MIP, 30 min a day for 10 weeks 
and de Jong et al. [15] noted improvements in inspiratory 
muscle endurance following training at 20%–40% MIP for 
20 min, five days a week for 6-weeks. Although the optimal 
training intensity, duration and frequency clearly remains to 
be elucidated, research suggests that the specific combina-
tion used may influence the specific respiratory parameters 
effected. Specifically, it appears that low intensity training 
elicits improvements in inspiratory muscle endurance whilst 
high-intensity training influences IMS [45]. Interestingly, 
in accord with whole body strength training regimens, it 
has been suggested that during the first four weeks IMT 
predominantly induces neural adaptations [7, 44], with any 
improvements thereafter considered to be largely related to 
morphological adaptations [21]. Therefore, given the 18% 
clinically meaningful improvement in S.Index observed in 
the current study, it could be postulated that 40% MIP is 
the minimum intensity required to elicit significant benefits 
in IMS. However, it appears that a longer duration and/
or greater resistance may be required to elicit changes in 
lung volume. Indeed, Enright et al. [18] found significant 
improvements in lung volume at 80% MIP resistance, but 
not 20% MIP, this study extends this finding to suggest that 
greater than 40% MIP is required. The current findings high-
light the importance of tailoring the resistance to the desired 
outcome, whilst being cognisant that lower resistances are 
likely to be associated with better long-term adherence and 
perceptions of feasibility and enjoyment [32].
Inspiratory muscle training engendered clinically mean-
ingful improvements in flow rate in those with CF (18.1%) 
but not in their healthy counterparts. This may be attribut-
able to the slightly, albeit not significantly, lower values at 
baseline in those with CF, given that baseline “fitness” is 
broadly associated with the magnitude of response to train-
ing interventions [49]. However, this finding may also reflect 
a better adherence to the IMT protocol in those with CF. 
Whilst measurement of adherence was beyond the scope of 
the present study, those with CF have been reported to enjoy 
and perceive the benefits of IMT for their health associated 
with CF [32]. An improved flow rate has been associated 
with greater capacity for gas exchange due to more time 
available for alveolar emptying [10], while reduced respira-
tory comfort has been attributed to decreases in inspira-
tory flow rate [31]. Therefore, it could be hypothesised that 
improving inspiratory flow rate may enhance the efficiency 
of the respiratory system and feelings of discomfort. Indeed, 
in chronic obstructive pulmonary disease (COPD), IMT has 
been shown to enable deeper breaths and higher inspiratory 
flows, reducing inspiratory effort and dyspnoea scores [13]. 
However, whether this is similarly applicable in those with 
CF requires further investigation.
This is the first study to investigate the influence of 
IMT on HRV in CF despite the inextricable associations 
and interrelations between cardiovascular and respiratory 
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systems [38, 62]. At rest, the CF group had a higher LF:HF, 
suggested to be indicative of a higher sympathetic activity 
[2] and in accord with previous studies [20, 33]. Although 
the exact mechanisms underpinning this CF-related adapta-
tion remain inconclusive at this time, such findings could 
be attributed to alterations in respiratory patterns [40], dif-
ferences in participant age and its interaction with disease 
progression [33], higher work of breathing [29] or, indeed, 
differences in the levels of catecholamines, between those 
with and without CF [63]. Whilst the decrease in LF and 
LF:HF in the CF group following IMT was not significant, 
the clinically meaningful decrease in VLF could result in a 
reduction in the sympathetic tone relative to parasympathetic 
tone [56]. Previous research has suggested that inspiratory 
muscle fatigue increases the metaboreflex, which increases 
peripheral sympathetic activity; improving respiratory mus-
cle function by IMT may therefore increase fatigue resist-
ance and lessen sympathetic outflow [19]. However, this 
remains speculative given the lack of power associated with 
this pilot study. Nonetheless, the current results are similar to 
previous IMT studies in healthy adults that reported 8-weeks 
IMT, 20 min a day at 30% MIP increased S.Index and HF 
and decreased LF [19], with others reporting the same pro-
tocol was associated with an increased lung volume and QoL 
[34]. However, the studies of Ferreira et al. [19] and Mello 
et al. [34] were of a longer duration and in older popula-
tions with cardiothoracic complications, which may explain 
the significant improvements in cardiac function. Previous 
research has shown that respiratory patterns alter autonomic 
cardiovascular modulation, especially with respect to HF 
[57], which could explain the increase in parasympathetic 
modulation observed in the current study. Further studies 
should seek to determine the acute HRV response during, 
and following, IMT.
Inspiratory muscle training may improve oxygen supply 
by augmenting tidal volume, leading to a reduction in chem-
oreflex activity and, consequently, decreased sympathetic 
nerve discharge [4, 48]. According to previous research in 
healthy adults, inspiratory loads lower than 60% of MIP do 
not engender diaphragm fatigue as the metaboreflex of the 
inspiratory muscles is not activated and therefore sympa-
thetic tone is not increased [8]. Reduced lung function is 
related to sympathetic overactivity in those with bronchiec-
tasis and COPD, suggesting an increased cardiorespiratory 
risk [43]. Therefore, if IMT has the potential to improve 
HRV, it may improve lung function in those with CF, or 
vice versa.
In accord with some [5], but not all [18], previous stud-
ies, IMT had no significant impact on QoL. However, it is 
important to acknowledge that Enright et al. [18] researched 
adults who may have had more severe impairments in lung 
function, and thus QoL, and improvements may therefore 
be more likely to be evident following IMT given the lower 
baseline. In children, the CFQ may also lack the sensitiv-
ity to reveal small treatment effects in stable patients, but 
no alternative scoring system for short-term changes in 
symptoms and clinical findings is currently available [5]. 
Alternatively, this discrepancy may be related to the length 
of the intervention, indicating that longer interventions 
are needed to induce significant improvements in QoL in 
children [28, 53]. Despite this, the change in the respira-
tory domain scores, while not statistically significant, was 
clinically meaningful post IMT. Furthermore, the respiratory 
domain, S.index and flow were significantly correlated fol-
lowing IMT. A recent systematic review reported that lung 
function was consistently associated with respiratory symp-
toms within the CFQ-R and should be considered an impor-
tant outcome measure in CF [24]. However, there is limited 
research regarding the relationship between QoL and IMT, 
with HRQoL remaining an underutilised tool that should be 
more widely incorporated into future IMT research.
Whilst there are numerous strengths, it is important to 
consider certain limitations in the interpretation of this 
study. We acknowledge the controversy that surrounds inter-
pretation of HF, LF and LF:HF [27], however, HRV is a 
non-invasive tool that provides prognostic insight into global 
cardiovascular health [47, 57, 60]. The small sample size 
limits our statistical power and a larger study is required to 
ratify our findings. Given the challenges of obtaining large 
sample sizes of participants with CF [36], the application 
of MCID suggests whilst our results are statistically signifi-
cant, they were also clinically meaningful, highlighting the 
potential impact of IMT within the CF population [3]. The 
short duration of our intervention may also be perceived 
as a limitation, although it also increases the ecological 
validity of the findings as it more closely replicates how 
IMT may be used as an adjunct therapeutic strategy. Indeed, 
individual responses to exercise training are highly variable 
and distinguishing patients with- and without-significant, 
and clinically relevant training responses is a key factor 
in the identification of effective interventions, ensuring a 
patient-centred approach. Furthermore, the consideration of 
intervention fidelity, adherence and the factors that underpin 
these, which were not assessed in the present study, must 
be considered in future studies wishing to investigate the 
potential therapeutic role of IMT in those with CF.
In conclusion, 4-weeks of IMT led to clinically significant 
increases in IMS and in the respiratory symptom domain, 
while potentially having important influences on the auto-
nomic nervous system in those with CF. Overall, preliminary 
indications suggest that IMT could be considered to benefit 
respiratory and cardiovascular function in children with CF.
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